So-called BACE drugs, biopharma’s next (and possibly doomed) hope for treating Alzheimer’s disease, have had a difficult run of form lately. First, two big trials from Merck came up short, and then another from Johnson & Johnson ran into damning safety problems.

And the latest data, on a BACE drug from Biogen, may only underline growing fears in Alzheimer’s research.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy